Regulatory

Wanbury’s Tanuku API plant clears South Korea MFDS cGMP audit with zero observations

This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the company’s Patalganga manufacturing facility in April 2026

  • By IPP Bureau | November 21, 2026

Wanbury Limited’s API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations.

The inspection was conducted by two senior inspectors from South Korea’s MFDS, a leading international pharmaceutical regulatory authority, covering the facility’s compliance with applicable Good Manufacturing Practices (cGMP) standards.

This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the company’s Patalganga manufacturing facility in April 2026, which was also concluded with zero observations.

These consecutive achievements reflect Wanbury Limited’s strong commitment to quality, regulatory compliance and operational excellence. The Company remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.